Boundless Bio Announces Portfolio Prioritization and Runway Extension
Provided By GlobeNewswire
Last update: May 23, 2025
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program
Read more at globenewswire.com
